Clinical trials: Low and Intermediate Risk Prostate Cancer
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00643994
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States
- Volunteers
- 379 people
- Sponsor
- Accuray Incorporated
Prostate Cancer
Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform
In this non-interventional study, men being seen by urologists in the course of their normal practice that present with clinical suspicion of prostate cancer (based on DRE, elevated Prostate Specific Antigen (PSA), and/or family…
- Trial name
- NCT04100811
- Where
- 3 sites in United States
- Volunteers
- 2,019 people
- Sponsor
- miR Scientific LLC
Prostate Cancer
A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
- Trial name
- NCT07492381
- Testing
- ALPFA BPH PFA System
- Volunteers
- 50 people
- Sponsor
- ALPFA Medical
Prostate Cancer
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.
- Trial name
- NCT02499848
- Testing
- PRX302
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Sophiris Bio Corp
Lymphoma, Non-Hodgkin, Neoplasms
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Study CC-90011-ST-001 is an open-label, Phase 1, dose escalation and expansion, First-In-Human (FIH) clinical study of CC-90011 in subjects with advanced unresectable solid tumors (enriched for grade 2 NENs, grade 2 NETs and…
- Trial name
- NCT02875223
- Testing
- CC-90011, Rifampicin, Itraconazole
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 75 people
- Sponsor
- Celgene
Low Risk Prostate Cancer, Intermediate Risk Prostate Cancer
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer
This prospective study assess the effectiveness and safety of hypofractionated proton radiotherapy in the treatment of intermediate and low risk prostate cancer.
- Trial name
- NCT03740191
- Testing
- EPIC questionnaire, kV x-ray images, Conebeam CT
- Where
- Austria
- Volunteers
- 5 people
- Sponsor
- EBG MedAustron GmbH
Prostate Cancer, Prostatic Cancer
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms
- Trial name
- NCT00643617
- Testing
- CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk
- Where
- 18 sites in United States
- Volunteers
- 307 people
- Sponsor
- Accuray Incorporated